New Drug Application Initiated with U.S. FDA for TAR-200, the First and Only Intravesical Drug Releasing System for Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer January ...
Medullary renal cell carcinomas are exceedingly rare and essentially uniformly and rapidly fatal. Expeditious diagnosis is crucial. Immediate treatment with a clinical trial or platinum-based ...
In our recent review, "State of the Art: The Microbiome in Bladder Cancer," we explored the complex relationship between different types of microbiome and bladder cancer (BCa). 1 We highlighted the ...
Radiotherapy with curative intent is a standard of care for localized prostate cancer. Conventionally fractionated radiotherapy involves smaller daily radiation doses spread over several weeks. There ...
Bilateral synchronous renal masses (BSRMs) are a rare finding, and the optimal treatment strategy remains undetermined. This study depicts the management of BSRM at eight European high-volume centers.
For patients with high-risk non-muscle-invasive bladder cancer (NMIBC) for whom bacillus Calmette-Guérin (BCG) treatment has failed, bladder preservation is a high priority. Immune checkpoint ...
Patients with prostate cancer are at increased risk of developing radiation-induced secondary bladder cancer (RT-BC) due to external radiation therapy (EBRT) or brachytherapy (BT) for prostate cancer.
Transurethral resection of bladder tumor (TURBT) remains the basis of bladder tumor diagnosis and an effective means of treating nonmuscle invasive bladder cancer (NMIBC). There are several ...
Advancements in microbiome research reveal its impact on cancer treatment outcomes, particularly in renal cell carcinoma (RCC). While immune checkpoint inhibitors (ICIs) have improved survival in ...